
Key Points
- 01FDA clears Medtronic’s Hugo robotic system for U.S. general surgery
- 02New indications cover upper and lower abdominal procedures, including hernia and gastric bypass
- 03Cleared procedures represent about 3.5 million U.S. surgeries annually
- 04Hugo procedures are growing more than twice as fast as the robotic-surgery market
FDA clearance expands Hugo’s U.S. indications
Medtronic plc has received U.S. Food and Drug Administration clearance for its Hugo robotic-assisted surgery system for use in general surgery procedures. The expanded 510(k) decision allows hospitals and surgical teams in the United States to use Hugo beyond its existing urology indications, broadening the range of soft-tissue operations that can be performed with the platform.
The new clearance covers all upper-abdominal general surgical procedures, including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repair, and small-bowel resection. It also includes lower-abdominal procedures such as inguinal hernia repair and appendectomy, adding a wide span of commonly performed operations to Hugo’s approved U.S. use.
Combined, the newly cleared procedures account for approximately 3.5 million surgeries annually in the United States, described as more than half of all soft-tissue procedures performed in the country each year. The move is intended to expand the range of procedures available on the system within U.S. hospitals and surgical centers.
Scope of general surgery coverage
The clearance extends Hugo’s reach into surgical specialties where Medtronic technologies in open and laparoscopic approaches have been used for more than a half century. By including both upper- and lower-abdominal procedures, the decision spans routine operations such as cholecystectomy and appendectomy as well as more complex interventions like Roux-en-Y gastric bypass and ventral hernia repair.
Matt Anderson, senior vice president and president of Medtronic’s Surgical business, said the system expands choice with a practical option to help hospitals address capacity and access challenges, while giving surgical teams more flexibility to meet patients’ needs across care settings. The broader indication set is intended to support adoption across diverse care environments and procedure types.
System design and technology features
Hugo is built around a modular design that lets surgical teams deploy only the robotic arms needed for a given procedure and position them according to their technique and the patient’s anatomy. The system incorporates an open console, designed to keep the surgeon visually and verbally connected with the operating-room team and the patient during robotic procedures.
Surgeons using Hugo can employ Medtronic’s LigaSure RAS Maryland instrument, which integrates vessel-sealing technology. Medtronic reports that this vessel-sealing technology has been used in more than 45 million open and laparoscopic procedures, and it is now available as a compatible tool within the Hugo robotic platform.
Growth trajectory and procedure volumes
Medtronic states that global procedure growth for the Hugo system is running at more than two times the overall robotic-surgery market. Cumulative procedures performed with Hugo are projected to surpass 50,000 by the end of Medtronic’s fiscal year, reflecting expanding use of the system across multiple regions and specialties.
General surgery already represents Hugo’s highest procedure growth specialty outside the United States, surpassing urology and gynecology. The newly granted U.S. general surgery clearance aligns the domestic indications with this global trend, creating the potential for similar growth patterns within the U.S. market.
Clinical evidence from hernia repair
The general-surgery submission to the FDA included hernia repair and followed Hugo’s December 2025 clearance for urologic procedures. As part of the evidence base, Medtronic reported results from Enable Hernia Repair, a prospective, multicenter, single-arm pivotal study of 193 patients undergoing inguinal or ventral robotic hernia repair with Hugo.
In this study, surgical success was 100%, defined as no conversion from Hugo to laparoscopy, open surgery, or another robotic system, against a prespecified performance goal of 85%. The surgical-site event rate through 30 days was 0.0% among 92 inguinal patients available for analysis and 2.1% among 94 ventral patients, with both cohorts meeting a predetermined 30% performance goal for that measure. Mean hospital stays were reported at 4.7 hours for inguinal patients and 6.7 hours for ventral patients.
Key Takeaways
- 01Medtronic’s Hugo platform now has U.S. clearance for a broad set of general surgery procedures, significantly expanding its potential clinical use beyond urology.
- 02The newly approved indications span high-volume upper- and lower-abdominal operations, positioning Hugo to participate in about 3.5 million U.S. surgeries annually.
- 03Robust growth trends and supportive hernia study data provide a clinical and commercial foundation for wider adoption of Hugo in general surgery settings.
References
- https://finance.yahoo.com/healthcare/articles/medtronic-announces-fda-clearance-general-110000749.html?.tsrc=rss
- https://www.investing.com/news/company-news/medtronic-receives-fda-clearance-for-hugo-system-in-general-surgery-93CH-5032307
- https://www.securities.io/fda-clears-medtronics-hugo-robot-for-general-surgery-in-the-u-s/
- https://www.tipranks.com/news/the-fly/medtronic-announces-fda-clearance-of-hugo-ras-for-general-surgery-procedures-thefly-news